Phase 1 Risk Clinical Trials
45 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 45 trials
Recruiting
Phase 1
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Acute Myeloid LeukemiaR/R AMLR/R HR-MDS+1 more
Genmab78 enrolled9 locationsNCT07384715
Recruiting
Phase 1Phase 2
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Acute Lymphoblastic LeukaemiaHigher Risk Myelodysplastic SyndromesAcute Myeloid Leukaemia
AstraZeneca84 enrolled30 locationsNCT07155226
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 1Phase 2
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
ParagangliomaPheochromocytomaSolid Tumor Cancer+17 more
Fundación de investigación HM25 enrolled1 locationNCT06607692
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
Breast ReconstructionGenetic PredispositionPerfusion; Complications+1 more
Duke University25 enrolled1 locationNCT07264790
Recruiting
Phase 1Phase 2
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited150 enrolled15 locationsNCT07226895
Recruiting
Phase 1
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Prostate CancerLocalized Prostate CarcinomaHigh-risk Prostate Cancer+2 more
Thomas Hope45 enrolled1 locationNCT07054346
Recruiting
Phase 1Phase 2
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Beijing Biotech36 enrolled1 locationNCT07502287
Recruiting
Phase 1
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Chronic Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+1 more
Crossbow Therapeutics, Inc.72 enrolled11 locationsNCT06994676
Recruiting
Phase 1
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Stage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8+1 more
University of California, Davis30 enrolled1 locationNCT05843448
Recruiting
Phase 1Phase 2
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center116 enrolled1 locationNCT03214562
Recruiting
Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+15 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT03630991
Recruiting
Phase 1
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma
Stephan Grupp MD PhD38 enrolled1 locationNCT07007117
Recruiting
Phase 1Phase 2
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
High Risk NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma
Roberto Chiarle42 enrolled2 locationsNCT06803875
Recruiting
Phase 1
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
High Risk NeuroblastomaRetinoblastomaRefractory Neuroblastoma+2 more
Stephan Grupp MD PhD45 enrolled1 locationNCT05650749
Recruiting
Phase 1Phase 2
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Acute Leukemia, High RiskMyelodysplastic Syndromes, High RiskHematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor
Ciusss de L'Est de l'Île de Montréal7 enrolled1 locationNCT07301866
Recruiting
Phase 1Phase 2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597